{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:33:41Z","timestamp":1787322821935,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Lipid-lowering reduces cardiovascular events (CVEs) in patients with coronary artery disease. We sought to understand lipid-lowering therapy (LLT), low-density lipoprotein cholesterol (LDL-C) levels, and CVEs after coronary revascularization (CR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We identified adults who underwent CR from 2014 to 2019 in linked datasets (IQVIA PharMetrics Plus health plan claims, IQVIA longitudinal prescription claims, and Prognos LDL-C database) using established methodology for extraction of deidentified claims data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 184,271 patients were identified, 73,619 (40.0%) of whom were hospitalized for myocardial infarction (MI) in the 30 days before the index revascularization. Utilization of LLT increased from 46.0% at 3 months prerevascularization to 92.7% 12 months postrevascularization. Only 56.4% of patients were prescribed high-intensity statins. In a subset of patients with LDL-C values (n = 5496), the mean (SD) LDL-C decreased from 108 (41) mg\/dL at 6 months prerevascularization to 82 (33) mg\/dL at 12 months postrevascularization (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001). At 12 months after revascularization, LDL-C was \u226570\u2009mg\/dL in 55.7% of patients with prior MI and 62.1% of patients without recent MI. CVEs rates (per 100 patient-years) at 12 months postrevascularization were 5.2 (95% confidence interval [CI], 5.1\u20135.3) for MI, 2.0 (95% CI, 1.9\u20132.0) for stroke, and 6.6 (95% CI, 6.5\u20136.7) for unstable angina.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Although LLT utilization increased after revascularization, high-intensity statins were underutilized. LDL-C levels remained above 70\u2009mg\/dL in more than half of the patients. Systematic efforts are needed after CR to improve lipid control and prevent recurrent CV events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/hpc.0000000000000426","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:27:17Z","timestamp":1787318837000},"page":"e0426","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Lipid-Lowering Treatment Patterns and Risk of Subsequent Cardiovascular Outcomes in Patients With Recent Coronary Revascularization"],"prefix":"10.1097","volume":"25","author":[{"given":"Casey","family":"Gazda","sequence":"first","affiliation":[{"name":"Division of Cardiology, University of North Carolina School of Medicine, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi B.","family":"Rane","sequence":"additional","affiliation":[{"name":"Amgen Inc., Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasikiran","family":"Nunna","sequence":"additional","affiliation":[{"name":"IQVIA, Plymouth Meeting, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zifan","family":"Zhou","sequence":"additional","affiliation":[{"name":"IQVIA, Plymouth Meeting, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Exter","sequence":"additional","affiliation":[{"name":"Amgen Inc., Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Pinto","sequence":"additional","affiliation":[{"name":"Amgen Inc., Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohdhar","family":"Habib","sequence":"additional","affiliation":[{"name":"Amgen Inc., Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine B.","family":"McGuiness","sequence":"additional","affiliation":[{"name":"IQVIA, Plymouth Meeting, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolin L.","family":"Wade","sequence":"additional","affiliation":[{"name":"IQVIA, Plymouth Meeting, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Cavender","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of North Carolina School of Medicine, Chapel Hill, NC"},{"name":"Clinical Research Alliance, University of North Carolina School of Medicine, Chapel Hill, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"R1-20260821","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/clc.23160","article-title":"Cardiovascular events and death after myocardial infarction or ischemic stroke in an older medicare population.","volume":"42","author":"Li","year":"2019","journal-title":"Clin Cardiol"},{"key":"R2-20260821","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jama.2010.1322","article-title":"Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. Research Support, Non-U.S. Gov\u2019t.","volume":"304","author":"Bhatt","year":"2010","journal-title":"JAMA"},{"key":"R3-20260821","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines.","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R4-20260821","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American college of cardiology solution set oversight committee.","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R5-20260821","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines.","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"R6-20260821","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"R7-20260821","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes.","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"R8-20260821","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes.","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"R9-20260821","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"R10-20260821","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome.","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"R11-20260821","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1185\/03007995.2011.567257","article-title":"Underutilization of statins in patients with type 2 diabetes in US clinical practice: a retrospective cohort study.","volume":"27","author":"Fu","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"R12-20260821","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/MAJ.0000000000000292","article-title":"Statin underuse and low prevalence of LDL-C control among U.S. adults at high risk of coronary heart disease.","volume":"348","author":"Gamboa","year":"2014","journal-title":"Am J Med Sci"},{"key":"R13-20260821","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCOUTCOMES.109.868505","article-title":"Medication underuse during long-term follow-up in patients with peripheral arterial disease.","volume":"2","author":"Hoeks","year":"2009","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R14-20260821","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1185\/03007995.2014.971151","article-title":"Statin treatment patterns and clinical profile of patients with risk factors for coronary heart disease defined by national cholesterol education program adult treatment panel III.","volume":"30","author":"Kern","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"R15-20260821","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jacc.2020.07.033","article-title":"Low-density lipoprotein cholesterol and adverse cardiovascular events after percutaneous coronary intervention.","volume":"76","author":"Sud","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R16-20260821","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1161\/CIRCULATIONAHA.112.108787","article-title":"Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains.","volume":"126","author":"Subherwal","year":"2012","journal-title":"Circulation"},{"key":"R17-20260821","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.2147\/TCRM.S216606","article-title":"Demographic and clinical characteristics of patients prescribed proprotein convertase subtilisin\/kexin type 9 inhibitor therapy and patients whose current lipid-lowering therapy was modified.","volume":"15","author":"Baum","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"R18-20260821","doi-asserted-by":"crossref","first-page":"100177","DOI":"10.1016\/j.ajpc.2021.100177","article-title":"Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC\/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States.","volume":"6","author":"Baum","year":"2021","journal-title":"Am J Prev Cardiol"},{"key":"R19-20260821","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ahj.2019.10.014","article-title":"Getting to an improved understanding of low-density lipoprotein-cholesterol and dyslipidemia management (GOULD): methods and baseline data of a registry of high cardiovascular risk patients in the United States.","volume":"219","author":"Cannon","year":"2020","journal-title":"Am Heart J"},{"key":"R20-20260821","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamacardio.2021.1810","article-title":"Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US.","volume":"6","author":"Cannon","year":"2021","journal-title":"JAMA Cardiol"},{"key":"R21-20260821","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jacc.2017.11.068","article-title":"Compliance with guideline-directed medical therapy in contemporary coronary revascularization trials.","volume":"71","author":"Pinho-Gomes","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R22-20260821","first-page":"685","article-title":"Patterns of statin use in a real-world population of patients at high cardiovascular risk.","volume":"22","author":"Lin","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"R23-20260821","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.amjcard.2013.04.041","article-title":"Trends in the prevalence, awareness, treatment and control of high low density lipoprotein-cholesterol among United States adults from 1999\u20132000 through 2009\u20132010.","volume":"112","author":"Muntner","year":"2013","journal-title":"Am J Cardiol"},{"key":"R24-20260821","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1001\/jamacardio.2016.5922","article-title":"Adoption of the 2013 American college of cardiology\/American heart association cholesterol management guideline in cardiology practices nationwide.","volume":"2","author":"Pokharel","year":"2017","journal-title":"JAMA Cardiol"},{"key":"R25-20260821","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.amjcard.2018.05.016","article-title":"Willingness to be reinitiated on a statin (from the reasons for geographic and racial differences in stroke study).","volume":"122","author":"Mefford","year":"2018","journal-title":"Am J Cardiol"},{"key":"R26-20260821","doi-asserted-by":"crossref","first-page":"e007370","DOI":"10.1161\/JAHA.117.007370","article-title":"Temporal trends of high-intensity statin therapy among veterans treated with percutaneous coronary intervention.","volume":"7","author":"Bin Abdulhak","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"R27-20260821","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1524-4733.2006.00163.x","article-title":"Reduced mortality rates after intensive statin therapy in managed-care patients.","volume":"10","author":"Fintel","year":"2007","journal-title":"Value Health"},{"key":"R28-20260821","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jamacardio.2016.4052","article-title":"Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease.","volume":"2","author":"Rodriguez","year":"2017","journal-title":"JAMA Cardiol"},{"key":"R29-20260821","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"R30-20260821","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis.","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"R31-20260821","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jamacardio.2017.2289","article-title":"Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease.","volume":"2","author":"Cannon","year":"2017","journal-title":"JAMA Cardiol"},{"key":"R32-20260821","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1001\/archinte.163.21.2576","article-title":"In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization.","volume":"163","author":"Aronow","year":"2003","journal-title":"Arch Intern Med"},{"key":"R33-20260821","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS).","volume":"74","author":"Koskinas","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R34-20260821","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1161\/CIRCULATIONAHA.120.046320","article-title":"Effect of evolocumab on atherogenic lipoproteins during the peri- and early postinfarction period: a placebo-controlled, randomized trial.","volume":"142","author":"Leucker","year":"2020","journal-title":"Circulation"}],"container-title":["Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/HPC.0000000000000426","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:27:22Z","timestamp":1787318842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/HPC.0000000000000426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/hpc.0000000000000426","relation":{},"ISSN":["1535-2811"],"issn-type":[{"value":"1535-2811","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]}}}